Table 2.
Surrogate neutralization for SARS-CoV-2 Omicron (B.1.1.529) BA. 2 in solid cancer patients.
Neutralization against Omicron (30% Cut-Off) | |||
---|---|---|---|
Positive | Negative | ||
Anti-RBD Ig > 210 U/mL | Adequate response | 2 | 35 |
Anti-RBD Ig < 210 U/mL | Inadequate response | 0 | 3 |
Total | 2 | 38 |